Capital Blue Cross is teaming up with the drug company to assist its members on discount medications.
Capital Blue Cross will become the first health plan in the nation to team up with Mark Cuban's Cost Plus Drugs, a drug company launched earlier this year, to help bring high-quality, lower-cost prescription drugs to its members as well as the communities it serves.
Cost Plus Drugs is providing the pharmaceutical industry transparent drug pricing and minimal markups and fees. The company charges consumers only 15% more than it pays to buy a drug from the manufacturer, along with a $3 per-prescription dispensing fee and shipping.
As a result, consumers can experience savings of up to 80% on some of the most commonly prescribed generic drugs.
Capital Blue Cross President and CEO Todd Shamash said the collaboration with the drug company will help bring lower-cost medications to members and nonmembers alike across our service area, "providing some much-needed relief to those struggling to pay for their vital – and sometimes life-saving – medications.”
“Our mission at Cost Plus Drugs is to ensure all consumers have access to the medications they need to be healthy – a goal Capital Blue Cross shares,” said Dr. Alex Oshmyansky, CEO of Mark Cuban Cost Plus Drug Company. “Working with a like-minded organization like Capital gives us more momentum to help people get the medications they need at costs they can afford.”
According to a September 2021 Gallup poll, 18 million Americans have been unable to afford at least one prescription medication for their household, and 1 in 10 Americans have skipped doses to save money. Both Capital Blue Cross and Cost Plus Drugs are dedicated to helping lower prescription drug costs to consumers so they don’t have to skip needed medications.
In 2023, Capital Blue Cross members will be able to use their insurance cards at Cost Plus Drugs, further increasing access and lowering out-of-pocket costs for Capital members and their families.
Emerging Therapies Committee at UC Davis Hits the Accelerator Not the Brake | AMCP 2024
April 18th 2024After the onboarding of cell and gene therapy bogged using normal pharmacy and therapeutics (P&T) committee procedures, UC Davis Health set up an emerging therapeutics committee to streamline and speed up the process of delivery expensive cell and gene therapies.
Read More
DC Roundtable: Patrick Cooney of The Federal Group Drops the Latest on PBM Legislation in Washington
April 11th 2024In this episode of "DC Roundtable," Peter Wehrwein, managing editor of Managed Healthcare Executive, spoke with Patrick Cooney, president of The Federal Group, a lobbying and strategic planning firm in Washington, D.C., about recent developments in Washington concerning PBMs.
Listen
2024 Emerging Leaders in Healthcare — Submit For a Chance to Be Featured in MHE's August Issue
April 18th 2024MHE Editors are seeking diverse healthcare professionals from different backgrounds and healthcare sectors, with individual interests. Eligible candidates are early or mid-career leaders with less than 10 years of experience. Award winners will enjoy complimentary passes to the PBMI Annual National Meeting in Orlando, Florida, from Sept. 4-6. Additional perks include a feature in our August issue, a subscription to MHE and more!
Read More